Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer, Urothelial/Bladder Cancer), By Technology (Cleavable, Non-cleavable Linker, Linkerless), And Segment Forecasts, 2022 - 2030

Antibody-Drug Conjugates Market Size, Share & Trends Analysis Report Application (Blood Cancer, Breast Cancer, Urothelial/Bladder Cancer), By Technology (Cleavable, Non-cleavable), By Payload Technology, And Segment Forecasts, 2022 - 2030

The global antibody drug conjugates market size is expected to reach over USD 22.87 billion by 2030, registering a CAGR of 16.4% during the forecast period, according to a new report by Grand View Research Inc. The presence of strong pipeline products and strategic initiatives undertaken by the key players are expected to drive the market growth during the forecast period.

Key players such as ADC Therapeutics, Seagen. Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca, Daiichi Sankyo, and others are collaborating to develop and commercialize products. For instance, in February 2022, Mersana Therapeutics, partnered with Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson Inc., for the research and development of novel ADCs to treat various cancers. Under this agreement, Janssen will pay Mersana Therapeutics USD 40.0 million upfront and potentially more than USD 1.0 billion in milestone-based payments for the development of new ADCs.

Extensive research and rising funding for the development of novel antibody-drug conjugates by pharmaceutical companies is projected to drive market growth. For instance, in April 2021, Adcendo and Adcentrx, two new startups raised funding of around USD 112.0 million for the development of ADCs with their new approach to the treatment of cancer. Adcendo raised USD 51.0 million for the development of new ADCs that target endocytic receptors, which play the role of the drug delivery body. Adcentrx raised USD 50.0 million for its ADC research programs.

Additionally, in March 2022, ImmunoGen, Inc. announced the submission of biological license application (BLA) to the U.S. FDA for mirvetuximab soravtansine used as monotherapy in patients with ovarian cancer. It comprises alpha-binding antibody, cleavable linker, and the maytansinoid DM4 as payload to kill the targeted cancer cells.

Stringent reimbursement policies for ADCs may restrain the market growth due to the high cost associated with the treatment of ADCs as compared to the alternative conventional treatments such as monoclonal antibodies therapy & chemotherapy. This higher cost of treatment is expected to impede reimbursement coverage. For instance, in February 2020, National Centre for Pharmaco economics, Ireland, gave a negative review for Roche’s Kadcyla (trastuzumab emtansine) for reimbursement consideration due to its low cost-effectiveness.

The rising geriatric population coupled with the increasing prevalence of the diseases such as multiple myeloma (MM) is expected to drive demand for ADCs, thereby driving the market growth during the forecast period. Multiple myeloma (MM) is a disease of the aging population, and nearly 30,000 new cases of MM were diagnosed in 2021. The median age of diagnosed patients with multiple myeloma is 70 years. Thus, the introduction of new ADCs for the treatment of multiple myeloma is expected to boost market growth. For instance, in August 2020, the FDA approved BLENREP by GlaxoSmithKline as a monotherapy to treat relapsed or refractory multiple myeloma. Blenrep was the first anti-BCMA therapy approved for the treatment of multiple myeloma.

Antibody drug Conjugates Market Report Highlights
Breast cancer dominated the market in 2021, owing to the high prevalence of breast cancer and the availability of multiple ADC products for treating the breast cancer

Cleavable linker segment dominated the market in 2021 due to the rising adoption of cleavable linker technology in commercial ADC products and the advantages associated with the use of cleavable linkers over other linker technology

Based on linker type, others segment dominated the market in 2021 due to presence of a large number of highly effective linkers in market such as SMCC, SPP, MCC, maleimide tetrapeptide, CL2A, and MC (Maleimidocaproyl) used to deliver payloads to their target sites.

North America dominated the market in 2021 due to the presence of key pharmaceutical companies such as Pfizer, Inc, Gilead Life Sciences, Inc., and Seagen, Inc. and their strategic initiatives for the development of new ADCs

Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country wise market estimation using bottom-up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.11.1 Objective 1:
1.11.2 Objective 2:
1.11.3 Objective 2:
1.11.4 Objective 4
1.12 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Industry Outlook
3.1 Market Variable Analysis
3.2 Penetration and Growth Prospect Mapping
3.3 Driver Impact Analysis
3.3.1 Presence of strong product pipeline
3.3.2 Growing geriatric population base
3.3.3 Increasing incidence and prevalence of cancer
3.4 Market Restraint Analysis
3.4.1 High manufacturing cost and downstream processing challenges for ADCs
3.4.2 Analytical Challenges for ADc
3.4.3 Stringent Reimbursement policies for ADCs
3.5 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.6 Porter’s Five Forces Analysis
3.7 Qualitative Analysis for ADC Development Platforms
3.7.1 Creative Biolabs
3.7.2 Mersana Therapeutics
3.7.3 Heidelberg Pharma
3.7.4 Synaffix BV
3.7.5 NBE therapeutics
3.7.6 VERAXA
3.7.7 Tubulis GmbH
3.7.8 Byondis Platform
3.7.9 ImmunoGen, Inc.
3.7.10 RemeGen
3.7.11 WuXi Biologics
3.7.12 Merck KGaA
3.7.13 Ambrx
Chapter 4 APPLICATION BUSINESS ANALYSIS
4.1 Antibody Drug Conjugates Market: Application Movement Analysis
4.2 Blood Cancer
4.2.1 Blood Cancer market estimates and forecast, 2017 - 2030
4.2.2 Leukemia
4.2.2.1 Leukemia market estimates and forecast, 2017 - 2030
4.2.3 Multiple Myeloma
4.2.3.1 Multiple Myeloma market estimates and forecast, 2017 - 2030
4.2.4 Lymphoma
4.2.4.1 Lymphoma market estimates and forecast, 2017 - 2030
4.3 Breast Cancer
4.3.1 Breast Cancer market estimates and forecast, 2017 - 2030
4.4 Urothelial/Bladder Cancer
4.4.1 Urothelial Cancer market estimates and forecast, 2017 - 2030
4.5 Others
4.5.1 Others market estimates and forecast, 2017 - 2030
Chapter 5 TECHNOLOGY BUSINESS ANALYSIS
5.1 Antibody Drug Conjugates Market: Technology Movement Analysis
5.2 By Type
5.2.1 Cleavable Linker
5.2.1.1 Cleavable Linker market estimates and forecast, 2016-2028
5.2.2 Non-cleavable Linker
5.2.2.1 Non-cleavable Linker market estimates and forecast, 2016-2028
5.2.3 Linkerless
5.2.3.1 Linkerless market estimates and forecast, 2016-2028
5.3 By Linker Technology
5.3.1 VC
5.3.1.1 VC (valine-citrulline) market estimates and forecast, 2017 - 2030
5.3.2 Sulfo-SPDB
5.3.2.1 Sulfo-spdb market estimates and forecast, 2017 - 2030
5.3.3 VA (Valine Alanine)
5.3.3.1 VA (Valine alanine) market estimates and forecast, 2017 - 2030
5.3.4 Hydrazone
5.3.4.1 Hydrazone market estimates and forecast, 2017 - 2030
5.3.5 Others
5.3.5.1 Others market estimates and forecast, 2017 - 2030
5.4 By Payload
5.4.1 MMAE
5.4.1.1 MMAE market estimates and forecast, 2017 - 2030
5.4.2 MMAF
5.4.2.1 MMAF market estimates and forecast, 2017 - 2030
5.4.3 DM4
5.4.3.1 DM4 market estimates and forecast, 2017 - 2030
5.4.4 Camptothecin
5.4.4.1 Camptothecin market estimates and forecast, 2017 - 2030
5.4.5 Others
5.4.5.1 Others market estimates and forecast, 2017 - 2030
Chapter 6 Regional Business Analysis
6.1 Antibody Drug Conjugates Market: Regional Movement Analysis
6.2 NORTH AMERICA
6.2.1 North America Antibody drug conjugates market estimates and forecasts, 2017 - 2030 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. Antibody drug conjugates market estimates and forecasts, 2017 - 2030 (USD Million)
6.2.3 CANADA
6.2.3.1 Canada Antibody drug conjugates market estimates and forecasts, 2017 - 2030 (USD Million)
6.3 EUROPE
6.3.1 EUROPE Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.3.2 UK
6.3.2.1 UK Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.3.3 GERMANY
6.3.3.1 Germany Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.3.4 ITALY
6.3.4.1 Italy Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.3.5 SPAIN
6.3.5.1 Spain Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.3.6 FRANCE
6.3.6.1 France Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.4 Asia Pacific
6.4.1 ASIA PACIFIC Antibody drug conjugates MARKET ESTIMATES AND FORECAST, 2017 - 2030 (USD Million)
6.4.2 JAPAN
6.4.2.1 Japan Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.4.3 CHINA
6.4.3.1 China Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.4.4 INDIA
6.4.4.1 India Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.4.5 AUSTRALIA
6.4.5.1 Australia Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.4.6 South Korea
6.4.6.1 South Korea Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.5 Latin America
6.5.1 Latin America Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.5.2 BRAZIL
6.5.2.1 Brazil Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.5.3 MEXICO
6.5.3.1 Mexico Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.5.4 ARGENTINA
6.5.4.1 Argentina Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.6 Middle East & Africa
6.6.1 Middle East & Africa Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.6.2 SOUTH AFRICA
6.6.2.1 South Africa Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.6.3 SAUDI ARABIA
6.6.3.1 Saudi Arabia Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.6.4 UAE
6.6.4.1 UAE Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
Chapter 7 Competitive Landscape
7.1 Major deals & strategic alliances analysis
7.1.1 New product launch
7.1.2 Mergers and acquisitions
7.1.3 Expansion
7.1.4 Partnerships
7.2 Vendor Landscape
7.2.1 List of key distributors and channel partners
7.3 Public Companies
7.3.1 Company market position analysis
7.3.2 Competitive Dashboard Analysis
7.4 Private Companies
7.4.1 List of key emerging companies/Technology disruptors/ innovators
Chapter 8 COMPANY PROFILES
8.1 Takeda Pharmaceutical Company Limited
8.1.1 Company overview
8.1.2 Financial Performance
8.1.3 Product benchmarking
8.1.4 Strategic initiatives
8.2 F. Hoffmann-La Roche Ltd.
8.2.1 Company overview
8.2.2 Financial Performance
8.2.3 Product benchmarking
8.2.4 Strategic initiatives
8.3 Pfizer, Inc.
8.3.1 Company overview
8.3.2 Financial Performance
8.3.3 Product benchmarking
8.3.4 Strategic initiatives
8.4 AstraZeneca
8.4.1 Company overview
8.4.2 Financial performance
8.4.3 Product benchmarking
8.4.4 Strategic initiatives
8.5 Gilead Sciences, Inc.
8.5.1 Company overview
8.5.2 Financial performance
8.5.3 Product benchmarking
8.5.4 Strategic initiatives
8.6 Astellas Pharma Inc.
8.6.1 Company overview
8.6.2 Financial Performance
8.6.3 Product benchmarking
8.6.4 Strategic initiatives
8.7 Seagen, Inc.
8.7.1 Company overview
8.7.2 Financial Performance
8.7.3 Product benchmarking
8.7.4 Strategic initiatives
8.8 Daiichi Sankyo Company, Limited
8.8.1 Company overview
8.8.2 Financial Performance
8.8.3 Product benchmarking
8.8.4 Strategic initiatives
8.9 GlaxoSmithKline Plc.
8.9.1 Company overview
8.9.2 Financial Performance
8.9.3 Product benchmarking
8.9.4 Strategic initiatives
8.10 ADC Therapeutics SA
8.10.1 Company overview
8.10.2 Financial Performance
8.10.3 Product benchmarking
8.10.4 Strategic initiatives
8.11 Synaffix BV
8.11.1 Company overview
8.11.2 Product benchmarking
8.11.3 Strategic initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings